Endorotor Resection In Refractory Barrett's Dysplasia Patients
NCT: NCT03364114 · TERMINATED
Brief Summary
The aim of the clinical trial is to evaluate the EndoRotor®'s ability to completely remove areas of Barrett's esophagus considered refractory after 3 failed ablation treatments (Radiofrequency Ablation (RFA) and/or Cryotherapy) or in patients with at least 1 failed ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours.
Frequently Asked Questions
What is Endorotor Resection In Refractory Barrett's Dysplasia Patients?
Endorotor Resection In Refractory Barrett's Dysplasia Patients is a clinical trial registered under NCT03364114. Current status: TERMINATED.
What is the status of NCT03364114?
The current status of NCT03364114 (Endorotor Resection In Refractory Barrett's Dysplasia Patients) is: TERMINATED.
When did Endorotor Resection In Refractory Barrett's Dysplasia Patients start?
Endorotor Resection In Refractory Barrett's Dysplasia Patients started on 2018-02-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.